Our mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. We are driven by a desire to make the medicines of tomorrow a reality.
Goals and Strategy
The Proprietary Development segment is becoming increasingly important: in 2017, the first proprietary program progressed into a pivotal clinical trial. An additional four programes are in clinical development.
Innovative technologies and smart development strategies are central to our approach. Success is created by our employees, who collaborate closely across all disciplines.
In the Partnered Discovery segment, we identify optimized therapeutic antibodies on behalf of partners. In 2017, Tremfya® was the first product derived from a partnership to receive market approval.
MorphoSys's goal is to develop exceptional biopharmaceuticals to improve the lives of patients suffering from serious diseases. With the successful transformation from a technology provider to a drug development company, we are well on the way to achieving this goal.
MOR106 – The first Ylanthia antibody in clinical development, investigated against atopic dermatitis.
In cooperation with our partner Galapagos we develop the antibody against inflammatory skin diseases.Find out more
MOR208 – A possible new treatment option for patients with blood cancer
MOR208 is being developed in a pivotal clinical trial for the treatment of malignant B cell diseases.Find out more
Tremfya® – The first HuCAL antibody with market approval in the United States, Europe and Canada for the treatment of moderate to severe psoriasis.
The compound is marketed by our partner Janssen and investigated in additional indications.Find out more